Maria Di Perna
Overview
Explore the profile of Maria Di Perna including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
57
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
De Novellis D, Derudas D, Vincelli D, Fontana R, Pepa R, Palmieri S, et al.
Eur J Haematol
. 2024 Oct;
114(1):105-114.
PMID: 39370303
Isatuximab, a novel anti-CD38 monoclonal antibody, is approved in combination with carfilzomib and dexamethasone (Isa-Kd) in relapsed/refractory multiple myeloma (RRMM) patients. Because of its recent introduction, real-world efficacy and safety...
2.
De Novellis D, Fontana R, Palmieri S, Pepa R, Di Perna M, Cetani G, et al.
Target Oncol
. 2023 Sep;
18(6):885-892.
PMID: 37747623
Background: Daratumumab, an anti-CD38 monoclonal antibody, is used for treatment of multiple myeloma (MM) and light chain amyloidosis at an intravenous dosage of 16 mg/kg or at a subcutaneous fixed...
3.
Iula R, De Novellis D, Trastulli F, Pepa R, Fontana R, Carobene A, et al.
Front Oncol
. 2022 Dec;
12:1026251.
PMID: 36457484
Belantamab-mafodotin is an innovative and selective treatment for multi-refractory/relapsed multiple myeloma (MM) patients; however, available real-life experiences on efficacy and safety are limited. In this real-world multicentric retrospective study, we...
4.
Cerchione C, De Renzo A, Nappi D, Di Perna M, Pepa R, Pugliese N, et al.
Support Care Cancer
. 2019 Jan;
27(5):1587-1588.
PMID: 30671660
No abstract available.
5.
Tenofovir vs lamivudine for the prevention of hepatitis B virus reactivation in advanced-stage DLBCL
Picardi M, Pepa R, Giordano C, Zacheo I, Pugliese N, Mortaruolo C, et al.
Blood
. 2018 Dec;
133(5):498-501.
PMID: 30530802
No abstract available.
6.
Cerchione C, Nappi D, Pareto A, Di Perna M, Zacheo I, Picardi M, et al.
Support Care Cancer
. 2018 Mar;
26(9):3111-3116.
PMID: 29574618
Despite novel agents, multiple myeloma is still an incurable disease, especially for elderly and frail patients, who are difficult to manage for concomitant comorbidities as the therapeutic options are limited...
7.
Pepa R, Picardi M, Giordano C, Zacheo I, Pugliese N, Cerchione C, et al.
Br J Haematol
. 2017 Jul;
182(5):715-718.
PMID: 28737231
No abstract available.
8.
Cerchione C, Nappi D, Di Perna M, Zacheo I, Migliaccio I, Salvatore D, et al.
Clin Case Rep
. 2017 Apr;
5(4):505-507.
PMID: 28396778
In this report, we would like to highlight the efficacy of bendamustine in a heavily pretreated patient, also refractory to pomalidomide. It is conceivable that different therapy combinations in heavily...
9.
Cerchione C, Nappi D, Di Perna M, Zacheo I, Pareto A, Picardi M, et al.
Case Rep Hematol
. 2016 Nov;
2016:6745286.
PMID: 27867671
The clinical management of relapsed/refractory multiple myeloma and the correct choice of the most suitable therapy in heavily pretreated and fragile patients are tough clinical issues for clinicians. In advanced...
10.
Cerchione C, De Renzo A, Di Perna M, Pepa R, Pugliese N, Catalano L, et al.
Support Care Cancer
. 2016 Nov;
25(3):839-845.
PMID: 27812763
Background: In this prospective study, the impact of granulocyte colony-stimulating factors (G-2 CSF) administered during induction treatment with bendamustine plus rituximab for indolent non- Hodgkin Llymphoma (NHL) was evaluated by...